Rani Therapeutics Holdings, Inc.
$0.97
▲
4.27%
2026-04-21 09:03:01
www.ranitherapeutics.com
NGM: RANI
Explore Rani Therapeutics Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$118.3 M
Current Price
$0.97
52W High / Low
$3.87 / $0.39
Stock P/E
—
Book Value
$0.34
Dividend Yield
—
ROCE
-83.37%
ROE
-1.82%
Face Value
—
EPS
$-0.45
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
69
Beta
0.66
Debt / Equity
10.4
Current Ratio
4.21
Quick Ratio
4.21
Forward P/E
-3.61
Price / Sales
45.19
Enterprise Value
$36.91 M
EV / EBITDA
-0.99
EV / Revenue
22.6
Rating
Strong Buy
Target Price
$7
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Hyperion DeFi, Inc. | $4.28 | — | $48.76 M | — | -38.69% | -3.24% | $17.18 / $1.02 | $4.73 |
| 2. | Sagimet Biosciences Inc. | $6.44 | — | $206.19 M | — | -51.08% | -38.2% | $11.41 / $2.02 | $3.42 |
| 3. | Compass Therapeutics, Inc. | $5.42 | — | $1.08 B | — | -35.42% | -41.29% | $6.88 / $1.6 | $1.1 |
| 4. | Acrivon Therapeutics, Inc. | $1.86 | — | $68.97 M | — | -73.75% | -53.86% | $3.56 / $1.05 | $3.56 |
| 5. | Trevi Therapeutics, Inc. | $15.4 | — | $1.96 B | — | -26.85% | -30.23% | $15.76 / $5.38 | $1.43 |
| 6. | Protagonist Therapeutics, Inc. | $104.42 | — | $6.74 B | — | -25.39% | -20.18% | $107.84 / $41.28 | $9.82 |
| 7. | Apogee Therapeutics, Inc. | $90.92 | — | $6.41 B | — | -31.41% | -31.57% | $95.31 / $31.38 | $13.21 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 1.46 M | 0 M | 0 M | 0.17 M | 1.03 M |
| Operating Profit | -8.54 M | -7.26 M | -10.51 M | -12.01 M | -11.24 M |
| Net Profit | -10.3 M | -5.41 M | -6.69 M | -7.26 M | -8.95 M |
| EPS in Rs | -0.1 | -0.05 | -0.07 | -0.07 | -0.09 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.63 M | 1.03 M | 0 M | 0 M |
| Operating Profit | -38.31 M | -49.6 M | -66.1 M | -63.45 M |
| Net Profit | -29.67 M | -30.02 M | -33.97 M | -30.59 M |
| EPS in Rs | -0.3 | -0.3 | -0.34 | -0.31 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 58.62 M | 36.63 M | 57.92 M | 108.03 M |
| Total Liabilities | 17.11 M | 33.14 M | 32.47 M | 34.02 M |
| Equity | 33.01 M | 1.99 M | 12.87 M | 36.85 M |
| Current Assets | 53.32 M | 29.74 M | 50.85 M | 100.92 M |
| Current Liabilities | 12.67 M | 19.89 M | 7.99 M | 4.82 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -18.71 M | -35.5 M | -51.24 M | -46.52 M |
| Investing CF | -7.03 M | 19.81 M | 29.86 M | -72.44 M |
| Financing CF | 40.3 M | 13.59 M | 0.23 M | 29 M |
| Free CF | -18.8 M | -35.76 M | -52.47 M | -48.13 M |
| Capex | -0.09 M | -0.27 M | -1.23 M | -1.62 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 11.63% | -11.06% | — | — |
| Profit Margin % | -2920.04% | — | — | — |
| Operating Margin % | -4824.9% | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -4914.69% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.